Quarterly ResultJun 2, 2026, 08:46 AM
INVO Fertility FY2025 Revenue +5% to $6.84M; Net Loss $(5.3)M
AI Summary
INVO Fertility announced its fiscal year 2025 financial results, reporting a 5% increase in total revenue to $6.84 million and an improved net loss from continuing operations of $(5.3) million compared to $(7.7) million in FY2024. The company also highlighted significant balance sheet strengthening with $11.5 million in recent financing, the acquisition of Family Beginnings in Indiana, and expansion of its clinic network and intellectual property. Management expressed optimism for future growth through organic initiatives and strategic acquisitions.
Key Highlights
- Total revenue increased 5% to $6,841,250 for fiscal year 2025, up from $6,532,000 in FY2024.
- Net loss from continuing operations improved to $(5.3) million in FY2025 from $(7.7) million in FY2024.
- Adjusted EBITDA was $(3.2) million in FY2025, compared to $(2.2) million in FY2024.
- Secured $11.5 million in aggregate gross proceeds from financing transactions in December 2025 and January 2026.
- Acquired Indiana-based Family Beginnings in February 2026, adding a fourth US clinic.
- Family Beginnings generated approximately $1.2 million in revenue and $0.2 million in net income.
- Issued a new patent for its modified INVOcell device, extending protection through 2040.
- Balance sheet strengthened with Series C-2 Preferred Stock converted/retired and warrant liabilities eliminated.
Price Impact
More from IVF